Stable targeted integration

JP2024099583A5Inactive Publication Date: 2024-11-14EMD MILLIPORE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024063216
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-18
Filing Date
2024-04-10
Publication Date
2024-11-14
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Traditional cell line engineering methods for recombinant therapeutic protein expression result in unstable cell lines with varying expression levels and protein heterogeneity due to random transgene integration, necessitating the need for site-specific targeted integration at suitable genomic locations.

Method used

Integration of exogenous sequences into predetermined genomic loci, such as NCBI reference sequences NW_003613934.1, NW_003614159.1, and NW_003613732.1, using target-directed endonucleases and donor polynucleotides to ensure stable and predictable expression without interfering with cell function.

Benefits of technology

Achieves stable, efficient, and consistent expression of exogenous sequences, preventing gene silencing and cellular abnormalities, with predictable protein production levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

To provide methods for integrating exogenous sequences in genomic loci, where the integration is stable and the exogenous sequence can function predictably and reliably.SOLUTION: The invention provides a method of identifying and verifying suitable genomic locations in a Chinese hamster ovary cell (CHO) and other cells for successful integration of therapeutic protein cassettes or other exogenous sequences.SELECTED DRAWING: Figure 1A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 835,810, filed April 18, 2019, which is hereby incorporated by reference in its entirety as part of this specification.

[0002] Technical Field The present disclosure relates to the stable integration of exogenous sequences into genomic loci where the exogenous sequences can function in a predictable and reliable manner. [Background technology]

[0003] Background technology Traditional cell line engineering approaches involve randomly inserting transgenes into the genome of host cells. Such engineering approaches have led to the development of highly productive cell lines for recombinant therapeutic protein expression. However, such engineering methods lead to unstable cell lines and clonal populations with significantly different expression levels and protein heterogeneity in the expression of the same molecule. To avoid these problems, site-specific targeted integration of transgenes is desired for recombinant therapeutic protein expression. Summary of the Invention [Problem to be solved by the invention]

[0004] The key to successful site-specific targeted transgene integration is a suitable genomic location (i.e., "safe harbor") for integration. This location must be amenable to transgene or exogenous sequence insertion, must allow stable and predictable expression of the transgene, and must not interfere with cell growth and function. In human-derived cell lines, suitable sites have been identified in the AAVS1 locus, but in many cells, viable sites for therapeutic protein production have not been identified. Thus, there is a need to identify and validate suitable genomic locations in Chinese hamster ovary cells (CHO) and other cells for successful integration of therapeutic protein cassettes or other exogenous sequences. [Means for solving the problem]

[0005] Summary of the Invention Among the various aspects of the present disclosure, there is provided a method for stably integrating at least one exogenous sequence into genomic DNA of a cell, the method comprising integrating the at least one exogenous sequence into a site within a genomic sequence selected from the NCBI reference sequences, NW_003613934.1, NW_003614159.1, NW_003613732.1, or homologs thereof.

[0006] Another aspect of the present disclosure includes a method for preparing a cell that contains an exogenous sequence integrated into genomic DNA, the method comprising: (a) introducing into a cell (i) a targeting endonuclease or a nucleic acid encoding a targeting endonuclease that targets a target site within a genomic sequence selected from NCBI reference sequences NW_003613934.1, NW_003614159.1, NW_003613732.1, or a homolog thereof, and (ii) a donor polynucleotide comprising an exogenous sequence; and b) maintaining the cells under conditions such that the exogenous sequence is integrated into the target site of the genomic sequence.

[0007] In some embodiments, the host cell, preferably a host cell line, is provided, which comprises at least one exogenous sequence integrated into genomic DNA at at least one predetermined target site suitable for stable integration.The suitable predetermined target site is preferably located in a genomic sequence selected from the group consisting of NCBI reference sequence, NW_003613934.1, NW_003614159.1, NW_003613732.1, or homologs thereof.

[0008] Other aspects and iterations of the disclosure are described in more detail below. [Brief description of the drawings]

[0009] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1A] FIG. 1A shows the RMCE-enabled cassettes used in hotspot identification and validation approach 1.

[0010] [Figure 1B] FIG. 1B shows the RMCE-enabled cassettes used in hotspot identification and validation approach 2.

[0011] [Diagram 2] Figure 2. Flow cytometry analysis of cell surface bound IgG. Left: D145 clone with GFP landing pad. Center: Random integration of IgG payload. Right: Targeted integration of IgG payload using Cre recombinase.

[0012] [Diagram 3] FIG. 3 shows positive junction PCR in pools containing targeted integration products but not the random integration pool.

[0013] [Figure 4] FIG. 4 shows ZFN targeting at the MP7 TI site and a cellular assay demonstrating positive ZFN cleavage activity.

[0014] [Diagram 5] FIG. 5 shows ZFN targeting at the MP58 TI site and cellular assays demonstrating positive ZFN cleavage activity.

[0015] [Figure 6] FIG. 6 shows monoclonal antibody production from the MP58 TI site. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Detailed Description of the Invention The present disclosure provides genomic loci for stable integration of exogenous sequences, and methods for integrating exogenous sequences into the genomic loci. Exogenous sequences are stably integrated into these genomic loci where they can function predictably and reliably. Thus, the genomic loci can be called "safe harbors". The integrated sequences remain in the genomic loci and are not excised or altered in any way. For example, the integrated sequences and adjacent sequences are not subject to gene silencing or position effect. In addition, the integrated exogenous sequences do not affect the function of genes or other chromosomal sequences in cells, i.e., do not change global or local gene expression, are free of cellular abnormalities or defects, are free of positional mutations or other side effects, etc. Furthermore, when the exogenous sequences code for proteins or RNA molecules, the expression of the exogenous sequences is stable, efficient, consistent, and predictable.

[0017] (I) Genomic loci for stable integration One aspect of the present disclosure provides mammalian genomic loci into which exogenous sequences can be integrated and which can function predictably and reliably. Genomic loci suitable for stable integration are located within genomic sequences selected from NCBI Reference Sequences (RefSeq) NW_003613934.1 (CriGri_1.0 scaffold 979), NW_003614159.1 (CriGri_1.0 scaffold 3466), NW_003613732.1 (CriGri_1.0 scaffold 1721), or homologs thereof. The above RefSeq is a contig / scaffold from the Chinese hamster genome, but homologous sequences are also present in the genomes of other mammals (e.g., human, mouse, rat, monkey, dog, cow, etc.) and can be used for stable integration in these mammalian cells.

[0018] A preferred locus is the region from bp 1,090,000 to bp 1,127,000 of NW_003613934.1 (CriGri_1.0 scaffold 979), which is flanked by the 5' transfer RNA lysine (Trnak) gene and the 3' peroxisomal NADH pyrophosphatase enzyme (NUDT12) gene. Another preferred locus is the region from bp 365,000 to bp 395,000 of NW_003614159.1 (CriGri_1.0 scaffold 3466), which is flanked by the 5' RAB6 interacting golgin (Gorab) gene and the 3' paired mesodermal homeobox protein 1 (Prrx1). Another preferred locus is the region from bp 1,935,000 to bp 1,985,000 of NW_003613732.1 (CriGri_1.0 scaffold 1721), which is flanked by the alpha-mannosidase 2 (Man2a1) gene on the 5' side and the transmembrane protein 232 (Tmem232) gene on the 3' side.

[0019] The more precise insertion position of each preferred locus was determined using the CHOK1S-HZDv1 assembly (GenBank assembly accession: GCA_900186095.1) as the reference genome. The D145 site is an insertion at (scaffold:position) 0:212, 357, 115. The MP7 site is an insertion at 0:217, 336, 436-217, 336, 341. The MP58 site is an insertion at 1:28, 570, 918-28, 570, 919.

[0020] II. Methods for stable integration of exogenous sequences Another aspect of the disclosure provides a method for stably integrating one or more exogenous sequences into genomic DNA of a cell, comprising integrating at least one exogenous sequence into a site in a genomic sequence selected from NCBI reference sequences NW_003613934.1, NW_003614159.1, NW_003613732.1, or homologs thereof, wherein the integrated sequences have no adverse effects on the cell, and the function of the integrated sequences is predictable, consistent, and reproducible.

[0021] In particular, the method includes incorporating into a cell (i) a targeting endonuclease that targets a target site within a genomic sequence selected from NCBI reference sequences NW_003613934.1, NW_003614159.1, NW_003613732.1, or homologs thereof, and (ii) a donor polynucleotide comprising at least one exogenous sequence, and maintaining the cell under conditions such that the at least one exogenous sequence is integrated into the genome of the cell.

[0022] Exogenous sequences As used herein, an "exogenous" sequence refers to a nucleotide sequence that is not native to the cell or that is in a location different from its natural location in the cell's genome.

[0023] In some embodiments, the exogenous sequence encodes a protein. The encoded protein can be a recombinant protein, a therapeutic protein, or an industrial protein. Non-limiting examples of suitable proteins include antibodies, antibody fragments, monoclonal antibodies, humanized antibodies, humanized monoclonal antibodies, chimeric antibodies, IgG molecules, IgG heavy chains, IgG light chains, IgA molecules, IgD molecules, IgE molecules, IgM molecules, vaccines, growth factors, cytokines, interferons, interleukins, hormones, clotting / coagulation factors, blood components, enzymes, nutraceutical proteins, functional fragments or variants of any of the foregoing, or fusion proteins comprising any of the foregoing proteins and / or functional fragments or variants thereof.

[0024] In other embodiments, the exogenous sequence encodes an RNA molecule, such as a non-coding RNA (ncRNA). Non-limiting examples of ncRNA include microRNA (miRNA), small interfering RNA (siRNA), guide RNA (gRNA), long non-coding RNA (lncRNA), long intergenic non-coding RNA (lincRNA), Piwi interacting RNA (piRNA), trans-acting RNA (rasiRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), mitochondrial tRNA (MT-tRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), SmY RNA, Y RNA, splice leader RNA (SL RNA), telomerase RNA component (TERC), fragments thereof, or combinations thereof. In certain embodiments, the exogenous sequence may encode an miRNA, siRNA, or gRNA.

[0025] In yet another embodiment, the exogenous sequence comprises at least one recognition sequence for at least one polynucleotide modifying enzyme. In other words, the exogenous sequence comprises a "landing pad", where the landing pad can be used for subsequent targeted integration of the exogenous sequence. The recognition sequence for the at least one polynucleotide modifying enzyme is generally not endogenously present in the cell genome. Selecting a recognition sequence that is not endogenously present in the cell can increase the rate of targeted integration and / or reduce potential off-target integration. The polynucleotide modifying enzyme can be a site-specific recombinase or a targeting endonuclease. Non-limiting examples of site-specific recombinases can include Bxb1 integrase, Cre recombinase, FLP recombinase, gamma delta resolvase, lambda integrase, phi C31 integrase, R4 integrase, Tn3 resolvase, and TP901-1 recombinase. Site-specific recombinases recognize specific recognition sequences (or recognition sites), as known in the art. For example, Cre recombinase recognizes LoxP sites, and FLP recombinase recognizes FRT sites. Contemplated targeting endonucleases include zinc finger nucleases (ZFNs), clustered regularly interspersed short palindromic repeats (CLIRs), and other nucleases. c Lustered r egularly i Interspersed s hort p alindromic r epeat) (CRISPR) / CRISPR-associated (Cas) (CRISPR / Cas) nuclease systems, CRISPR / Cas dual nickase systems, transcription activator-like effector nucleases (TALENs), meganucleases, or fusion proteins comprising a programmable DNA binding domain and a nuclease domain. Each of these targeting endonucleases is further described below in section (II)(c).

[0026] Multiple recognition sequences may be present within a single landing pad, and two or more polypeptide modifying enzymes may target the landing pad sequentially to insert two or more exogenous sequences. Alternatively, multiple recognition sequences may be present within a landing pad to insert multiple copies of the same exogenous sequence into the landing pad. When two exogenous sequences are targeted to a single landing pad, the landing pad includes a first recognition sequence for a first polynucleotide modifying enzyme (such as a first ZFN pair) and a second recognition sequence for a second polynucleotide modifying enzyme (such as a second ZFN pair). Alternatively, or in addition, individual landing pads containing one or more recognition sequences may be integrated into multiple locations within the cell genome, allowing integration of multiple copies of the exogenous sequence comprising the recombinant protein expression construct. Increased expression of proteins may be observed in cells transformed with multiple copies of the exogenous sequence comprising the expression construct. Alternatively, multiple unique exogenous sequences comprising different expression cassettes may be inserted, whether from the same or different landing pads, to simultaneously express multiple protein products. For example, an exogenous landing pad can include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more recognition sequences. In embodiments including more than one recognition sequence, the recognition sequences can be unique from one another (i.e., recognized by different polynucleotide modifying enzymes), be identical repeated sequences, or be a combination of repeated and unique sequences.

[0027] Those skilled in the art will readily appreciate that exogenous sequences may include additional sequences. For example, protein and RNA coding sequences may be operably linked to promoter regulatory sequences for expression in a cell of interest. In embodiments where the exogenous sequence codes for a protein, the exogenous sequence may be operably linked to a promoter sequence recognized by RNA polymerase II (Pol II). Pol II promoter regulatory sequences may be constitutive, regulated, or tissue-specific. Suitable constitutive Pol II promoter regulatory sequences include, but are not limited to, cytomegalovirus immediate early promoter (CMV), simian virus (SV40) promoter, adenovirus major late promoter, Rous sarcoma virus (RSV) promoter, mouse mammary tumor virus (MMTV) promoter, phosphoglycerate kinase (PGK) promoter, elongation factor (ED1)-alpha promoter, ubiquitin promoter, actin promoter, tubulin promoter, immunoglobulin promoter, fragments thereof, or any combination of the foregoing. Examples of suitable regulated Pol II promoter regulatory sequences include, but are not limited to, those regulated by heat shock, metals, steroids, antibiotics, or alcohol. Non-limiting examples of tissue-specific Pol II promoters include B29 promoter, CD14 promoter, CD43 promoter, CD45 promoter, CD68 promoter, desmin promoter, elastase-1 promoter, endoglin promoter, fibronectin promoter, Flt-1 promoter, GFAP promoter, GPIIb promoter, ICAM-2 promoter, INF-β promoter, Mb promoter, NphsI promoter, OG-2 promoter, SP-B promoter, SYN1 promoter, and WASP promoter. Promoter regulatory sequences can be wild-type or modified for more efficient or effective expression. Protein-coding sequences can also be linked to polyadenylation signals (e.g., SV40 polyA signal, bovine growth hormone (BGH) polyA signal, etc.), and / or transcription termination sequences.

[0028] In the embodiment where the exogenous sequence codes for RNA, the exogenous sequence is operably linked to a promoter regulatory sequence that is recognized by RNA polymerase III (Pol III). Examples of suitable Pol III promoters include, but are not limited to, mammalian U6, U3, H1, and 7SL RNA promoters. The RNA-coding exogenous sequence can also be linked to a transcription termination sequence.

[0029] In further embodiments, the exogenous sequence may be linked to sequences encoding hypoxanthine-guanine phosphoribosyltransferase (HPRT), dihydrofolate reductase (DHFR), and / or glutamine synthetase (GS), and HPRT, DHFR, and / or GS may be used as amplifiable selectable markers. The exogenous sequence may also be linked to sequences encoding at least one antibiotic resistance gene and / or sequences encoding a reporter protein, such as a fluorescent protein. Non-limiting examples of antibiotic resistance genes include blastidine, G418 (Geneticin 登録商標 ), hygromycin B, puromycin, phleomycin D1 (Zeocin 商標Suitable fluorescent proteins include, but are not limited to, green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreen1), yellow fluorescent proteins (e.g., YFP, EYFP, Citrine, Venus, YPet, PhiYFP, ZsYellow1), blue fluorescent proteins (e.g., BFP, EBFP, EBFP2, Azurite, mKalama1, GFPuv, Sapphire, T-sapphire), cyan fluorescent proteins (e.g., ECFP, Cerulean, CyPet, AmCyan1, Midoriishi-Cyan), red fluorescent proteins (e.g., mKate, mKate2, mPlum, DsRed, Monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRed1, AsRed2, eqFP611, mRasberry, mStrawberry, Jred), and orange fluorescent protein (e.g., mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato) or any other suitable fluorescent protein.

[0030] In some preferred embodiments, the landing pad is configured to facilitate recombinase-mediated cassette exchange (RMCE). In such embodiments, the landing pad comprises a sequence encoding a selectable marker, a sequence encoding a reporter protein, and a first and second recognition sequence of a polypeptide modifying enzyme. These elements are configured such that the sequence encoding the selectable marker and the sequence encoding the reporter protein are between the first and second recognition sequences of the polynucleotide modifying enzyme. In a particularly preferred embodiment, the sequence encoding the reporter protein encodes a green fluorescent protein such as GFP or turboGFP, the sequence encoding the selectable marker encodes puromycin, and the first and second recognition sequences are Lox sequences. Suitable Lox sequences include Lox71, Lox2272, Lox66, and Lox66 / 71.

[0031] Donor polynucleotide containing exogenous sequence The method includes introducing a donor polynucleotide containing an exogenous sequence into a cell. In some embodiments, the exogenous sequence in the donor polynucleotide can be flanked by sequences that have substantial sequence identity to sequences flanking a target site in a genomic sequence. For example, the exogenous sequence can be flanked by upstream and downstream sequences, where the upstream and downstream sequences have substantial sequence identity to sequences on either side of the target site in the genomic sequence. As used herein, an upstream sequence refers to a nucleic acid sequence that shares substantial sequence identity to a genomic sequence immediately upstream of the target site. Similarly, a downstream sequence refers to a nucleic acid sequence that shares substantial sequence identity to a genomic sequence immediately downstream of the target site. The upstream and downstream sequences in the donor polynucleotide containing the exogenous sequence are selected to promote recombination between the target genomic sequence and the donor polynucleotide (containing the exogenous sequence).

[0032] As used herein, the term "substantial sequence identity" refers to a sequence that has at least about 75% sequence identity.Thus, the upstream and downstream sequences in the donor polynucleotide that comprises an exogenous sequence can have about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the chromosomal sequence adjacent to the target site in the genome sequence (i.e., upstream or downstream).In certain embodiments, the upstream and downstream sequences in the donor polynucleotide that comprises an exogenous sequence have about 95% or 100% sequence identity with the chromosomal sequence adjacent to the target site in the genome sequence.The upstream or downstream flanking sequence can include about 10bp to about 2500bp. In one embodiment, the upstream or downstream sequence may comprise about 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 bp. Exemplary upstream or downstream flanking sequences may comprise about 20 to about 200 bp, 25 to about 100 bp, about 40 bp to about 60 bp. In certain embodiments, the upstream or downstream flanking sequence may comprise about 200 to about 500 bp.

[0033] In other embodiments, the exogenous sequence in donor polynucleotide can be flanked by the sequence recognized by targeting endonuclease.For example, the exogenous sequence can be flanked by upstream and downstream sequences, where the upstream and downstream sequences comprise the recognition sequence of targeting endonuclease, so that the targeting endonuclease introduces double-strand break at the target site in genome sequence and also introduces double-strand break in donor polynucleotide, so that the exogenous sequence is released from the rest of donor polynucleotide, and the exogenous sequence can be directly ligated to the cut genome sequence, so that the exogenous sequence is integrated into cell genome.

[0034] The donor polynucleotide comprising the exogenous sequence may be single-stranded or double-stranded, linear or circular. Generally, the donor polynucleotide is DNA. The donor polynucleotide may be a vector. Suitable vectors include plasmid vectors, phagemids, cosmids, artificial / minichromosomes, transposons, and viral vectors. Non-limiting examples of suitable plasmid vectors include pUC, pBR322, pET, pBluescript, and variants thereof. The donor polynucleotide may include additional regulatory sequences (e.g., enhancer sequences, Kozak sequences, polyadenylation sequences, transcription termination sequences, etc.), origins of replication, selectable marker sequences (e.g., antibiotic resistance genes), and the like. Additional information can be found in "Current Protocols in Molecular Biology" Ausubel et al., John Wiley & Sons, New York, 2003, or "Molecular Cloning: A Laboratory Manual" Sambrook & Russell, Cold Spring Harbor Press, Cold Spring Harbor, NY, 3 rd This can be found in the 2001 edition.

[0035] Targeting endonucleases The method also includes introducing a targeting endonuclease or a nucleic acid encoding the targeting endonuclease into the cell. The targeting endonuclease includes a DNA-binding domain and a nuclease domain. The DNA-binding domain of the targeting endonuclease is programmable, meaning that it can be designed or engineered to recognize and bind to different DNA sequences. In some embodiments, DNA binding is mediated by an interaction between the DNA-binding domain of the targeting endonuclease and the target DNA. Thus, the DNA-binding domain can be programmed to bind to a DNA sequence of interest by protein engineering. In other embodiments, DNA binding is mediated by a guide RNA that interacts with the DNA-binding domain of the targeting endonuclease and the target DNA. In such cases, the DNA-binding domain can be targeted to a DNA sequence of interest by designing a suitable guide RNA.

[0036] Suitable targeting endonucleases include zinc finger nucleases, clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) (CRISPR / Cas) nuclease systems, CRISPR / Cas nickase systems, transcription activator-like effector nucleases, meganucleases, or fusion proteins that contain programmable DNA binding domains and nuclease domains. Targeting endonucleases can include wild-type or naturally occurring DNA binding domains and / or nuclease domains, modified naturally occurring DNA binding domains and / or nuclease domains, synthetic or artificial DNA binding domains and / or nuclease domains, or combinations thereof.

[0037] (i) Zinc finger nuclease In some embodiments, the targeting endonuclease can be a zinc finger nuclease (ZFN). ZFN comprises a DNA-binding zinc finger region and a nuclease domain. The zinc finger region can comprise about 2 to 7 zinc fingers, for example about 4 to 6 zinc fingers, each zinc finger binds to three nucleotides, and the zinc fingers can be linked together using a suitable linker sequence. The zinc finger region can be engineered to recognize and bind to any DNA sequence. For example, Beerli et al. (2002) Nat. Biotechnol. 20:135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70: 313-340; Isalan et al. (2001) Nat. Biotechnol. 19:656-660; al.(2001)Curr.Opin.Biotechnol.12:632-637;Choo et al.(2000)Curr.Opin.Struct.Biol.10:411-416;Zhang et al.(2000)J.Biol.Chem.275(43):33850-33860;Doyon et al. al. (2008) Nat. Biotechnol. 26:702-708; and Santiago et al. See, e.g., E. et al. (2008) Proc. Natl. Acad. Sci. USA 105:5809-5814. Publicly available web-based tools for identifying potential target sites within DNA sequences and for designing zinc finger binding domains are known in the art.

[0038] ZFNs also include nuclease domains derived from any endonuclease or exonuclease. Non-limiting examples of endonucleases from which the nuclease domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. The cleavage domain can also be derived from an enzyme or part thereof that requires dimerization for cleavage activity. Two zinc finger nucleases may be required for cleavage, since each nuclease comprises a monomer of an active enzyme dimer. When two cleavage monomers are used to form an active enzyme dimer, the recognition sites of the two zinc finger nucleases are generally positioned such that the binding of the two zinc finger nucleases to their respective recognition sites positions the cleavage monomers in a spatial orientation with respect to each other, allowing the cleavage monomers to form an active enzyme dimer (e.g., by dimerizing). As a result, the near ends of the recognition sites can be separated by about 5 to about 18 nucleotides. For example, the near ends can be separated by about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotides.

[0039] In some embodiments, the nuclease domain can be derived from a type II-S restriction endonuclease. Type II-S endonucleases cleave DNA at sites that are typically several base pairs away from the recognition / binding site, and therefore have separable binding and cleavage domains. These enzymes are generally monomers that associate transiently to form dimers and cleave each strand of DNA at alternate positions. Non-limiting examples of suitable type II-S endonucleases include BfiI, BpmI, BsaI, BsgI, BsmBI, BsmI, BspMI, FokI, MboII, and SapI. In some embodiments, the nuclease domain can be a FokI nuclease domain or a derivative thereof. The type II-S nuclease domain can be modified to promote dimerization of two different nuclease domains. For example, the cleavage domain of FokI can be modified by mutating specific amino acid residues. As non-limiting examples, amino acid residues of the FokI nuclease domain at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531, 534, 537, and 538 are targeted for modification. For example, one modified FokI domain can include a Q486E, I499L, and / or N496D mutation, and another modified FokI domain can include an E490K, I538K, and / or H537R mutation.

[0040] The ZFN may further comprise at least one nuclear localization signal, a cell permeability domain, and / or a marker domain, which are described in section (II)(c)(vii) below.

[0041] (ii) CRISPR / Cas nuclease system In other embodiments, the targeting endonuclease can be an RNA-guided CRISPR / Cas nuclease system, which introduces a double-stranded break in DNA. The CRISPR / Cas nuclease system includes a CRISPR / Cas nuclease and a guide RNA.

[0042] CRISPR / Cas nucleases can be derived from Type I (i.e., IA, IB, IC, ID, IE or IF), Type II (i.e., IIA, IIB or IIC), Type III (i.e., IIIA or IIIB) or Type V CRISPR systems, which are present in a variety of bacteria and archaea.CRISPR / Cases Streptococcus sp.(Streptococcus pyogenes) Campylobacter sp.(Campylobacter jejuni) Francisella sp.(Francisella novicida) Acaryochloris sp.Acetohalobium sp.Acidaminococcus sp.Acidithiobacillus sp.Alicyclobacillus sp.Allochromatium sp.Ammonifex sp.Anabaena sp. Arthrospira sp. Bacillus sp. Burkholderiales sp. Caldicellulosiruptor sp. Candidatus sp. Clostridium sp. Crocosphaera sp. Cyanothece sp. Exiguobacterium sp. Finegoldia sp. Ctedonobacter sp. Lactobacillus sp. Lyngbya sp. Marinobacter sp. Methanohalobium sp. Microscilla sp. Microcoleus sp. Microcystis sp. Natranaerobius sp. Neisseria sp. Nitrosococcus sp. Nocardiopsis sp. Nodularia sp. Nostoc sp. Oscillatoria sp. Polaromonas sp. Pelotomaculum sp. Pseudoalteromonas sp. Petrotoga sp. Prevotella sp. Staphylococcus sp. Streptomyces sp sp., Synechococcus sp., or Thermosipho sp.

[0043] Non-limiting examples of suitable CRISPR nucleases include Cas proteins, Cpf proteins, Cmr proteins, Csa proteins, Csb proteins, Csc proteins, Cse proteins, Csf proteins, Csm proteins, Csn proteins, Csx proteins, Csy proteins, Csz proteins, and derivatives or variants thereof. In specific embodiments, the CRISPR / Cas nuclease can be a type II Cas9 protein, a type V Cpf1 protein, or a derivative thereof. In some embodiments, the CRISPR / Cas nuclease can be Streptococcus pyogenes Cas9 (SpCas9) or Streptococcus thermophilus Cas9 (StCas9). In other embodiments, the CRISPR / Cas nuclease can be Campylobacter jejuni Cas9 (CjCas9). In alternative embodiments, the CRISPR / Cas nuclease can be Francisella novicida Cas9 (FnCas9). In yet other embodiments, the CRISPR / Cas nuclease can be Francisella novicida Cpf1 (FnCpf1).

[0044] Generally, CRISPR / Cas nuclease comprises an RNA recognition and / or RNA binding domain, which interacts with guide RNA.CRISPR / Cas nuclease also comprises at least one nuclease domain with endonuclease activity.For example, Cas9 protein can comprise RuvC-like nuclease domain and HNH-like nuclease domain, and Cpf1 protein can comprise RuvC-like domain.CRISPR / Cas nuclease also can comprise DNA binding domain, helicase domain, RNase domain, protein-protein interaction domain, dimerization domain, and other domains.

[0045] CRISPR / Cas nucleases may further comprise at least one nuclear localization signal, a cell permeability domain, and / or a marker domain, which are described below in section (II)(c)(vii).

[0046] The CRISPR / Cas nuclease system also includes a guide RNA (gRNA). The guide RNA interacts with the CRISPR / Cas nuclease and guides the nuclease to a target site within the genomic sequence. The target site has no sequence restrictions except that it is adjacent to a protospacer adjacent motif (PAM). For example, PAM sequences for Cas9 include 3'-NGG, 3'-NGGNG, 3'-NNAGAAW, and 3'-ACAY, and PAM sequences for Cpf1 include 5'-TTN (where N is defined as any nucleotide, W is either A or T, and Y is either C or T). Each gRNA includes a sequence complementary to the target sequence (e.g., the gRNA for Cas9 is GN 17-20 GG). The gRNA also includes a scaffold sequence that forms a stem-loop structure and a single-stranded region. This scaffold region can be identical in every gRNA. In some embodiments, the gRNA can be a single molecule (i.e., sgRNA). In other embodiments, the gRNA can be two separate molecules (i.e., crRNA and tracrRNA).

[0047] (iii) CRISPR / Cas nickase system. In other embodiments, the targeting endonuclease can be a paired CRISPR / Cas nickase system. The CRISPR / Cas nickase system is similar to the above CRISPR / Cas nuclease system, except that the CRISPR / Cas nuclease is modified to only cleave a single strand of DNA. Thus, the single CRISPR / Cas nickase system creates a single-stranded break or nick in double-stranded DNA. Alternatively, the paired CRISPR / Cas nickase system (or dual nickase system) containing a pair of offset gRNAs can generate a single-stranded break in the opposite strand of DNA, thereby generating a double-stranded break in DNA.

[0048] CRISPR / Cas nucleases can be converted into nickases by one or more mutations and / or deletions. For example, Cas9 nickases can contain one or more mutations in one of the nuclease domains, where the one or more mutations can be D10A, E762A, and / or D986A in the RuvC-like domain, or the one or more mutations can be H840A, N854A, and / or N863A in the HNH-like domain.

[0049] (iv) Transcription activator-like effector nucleases In an alternative embodiment, the targeting endonuclease can be a transcription activator-like effector nuclease (TALEN). TALENs contain a DNA-binding domain composed of a highly conserved repeat sequence derived from a transcription activator-like effector (TALE) linked to a nuclease domain. TALEs are proteins secreted by the plant pathogen Xanthomonas and alter gene transcription in host plant cells (Bai et al., 2000, Mol. Plant Microbe Interact., 13(12):1322-9). TALE repeat arrays can be engineered through modular protein design to target any DNA sequence of interest. The nuclease domain of TALENs can be any nuclease domain described in section (II)(c)(i) above. In a specific embodiment, the nuclease domain is derived from FokI (Sanjana et al., 2012, Nat Protoc, 7(1):171-192).

[0050] TALENs may also contain at least one nuclear localization signal, a cell permeability domain, and / or a marker domain, which are described below in section (II)(c)(vii).

[0051] (v) Meganucleases or rare-cutting endonucleases In yet another embodiment, the targeting endonuclease can be a meganuclease or a derivative thereof. Meganucleases are endodeoxyribonucleases characterized by long recognition sequences (i.e., the recognition sequences generally range from about 12 base pairs to about 45 base pairs). As a result of this requirement, the recognition sequences generally occur only once in any given genome. Among meganucleases, a family of homing endonucleases named LAGLIDADG has become a useful tool for genome research and genome engineering (Arnould et al., 2011, Protein Engineering, Design & Selection, 24(1-2):27-31). Other suitable meganucleases can be I-CreI, I-Dmol, I-SceI, I-TevI ​​and variants thereof. Meganucleases can be targeted to specific chromosomal sequences by modifying their recognition sequences using techniques known to those skilled in the art.

[0052] In alternative embodiments, the targeting endonuclease can be a rare-cutting endonuclease or its derivatives.A rare-cutting endonuclease is a site-specific endonuclease, whose recognition sequence occurs rarely in a genome (preferably occurs only once in a genome).A rare-cutting endonuclease can recognize a 7-nucleotide sequence, an 8-nucleotide sequence, or a longer recognition sequence.Non-limiting examples of rare-cutting endonuclease include AscI, AsiSI, FseI, NotI, PacI, and SbfI.

[0053] The meganuclease or rare-cutting endonuclease may also comprise at least one nuclear localization signal, a cell permeability domain, and / or a marker domain, which are described below in section (II)(c)(vii).

[0054] (vi) a fusion protein containing a nuclease domain In yet another embodiment, the targeting endonuclease can be a fusion protein comprising a nuclease domain and a programmable DNA binding domain. The nuclease domain can be any of the nuclease domains described in section (II)(c)(i) above, a nuclease domain derived from a CRISPR / Cas nuclease (e.g., the RuvC-like nuclease domain or the HNH-like nuclease domain of Cas9, or the nuclease domain of Cpf1), or a nuclease domain derived from a meganuclease or a rare-cutting endonuclease.

[0055] The programmable DNA-binding domain of the fusion protein can be derived from a targeting endonuclease (i.e., a CRISPR / CAS nuclease or meganuclease) that has been engineered to lack all nuclease activity (i.e., catalytically inactive). Alternatively, the programmable DNA-binding domain of the fusion protein can be a programmable DNA-binding protein, such as, for example, a zinc finger protein or a TALE.

[0056] In some embodiments, the programmable DNA binding domain can be a catalytically inactive CRISPR / Cas nuclease whose nuclease activity has been eliminated by mutation and / or deletion. For example, the catalytically inactive CRISPR / Cas protein can be a catalytically inactive (DEAD) Cas9 (dCas9) whose RuvC-like domain contains D10A, E762A and / or D986A mutations and whose HNH-like domain contains H840A, N854A and / or N863A mutations. Alternatively, the catalytically inactive CRISPR / Cas protein can be a catalytically inactive (DEAD) Cpf1 protein whose nuclease domain contains the corresponding mutations. In yet other embodiments, the programmable DNA binding domain can be a catalytically inactive meganuclease whose nuclease activity has been eliminated by mutation and / or deletion, for example, the catalytically inactive meganuclease can contain a C-terminal truncation.

[0057] Fusion proteins containing a nuclease domain may also contain at least one nuclear localization signal, a cell permeability domain, and / or a marker domain, which are described in section (II)(c)(vii) below.

[0058] (vii) Any additional domains The targeting endonuclease may further comprise additional domains, for example, the targeting endonuclease may further comprise at least one nuclear localization signal, at least one cell permeability domain, and / or at least one marker domain.

[0059] In certain embodiments, the targeting endonuclease may comprise at least one NLS. Generally, the NLS comprises a stretch of basic amino acids. Nuclear localization signals are known in the art (e.g., Lange et al., J. Biol. Chem., 2007, 282:5101-5105). For example, in one embodiment, the NLS may be a monopartite sequence, such as PKKKRKV (SEQ ID NO: 1) or PKKKRRV (SEQ ID NO: 2). In another embodiment, the NLS may be a bipartite sequence, such as KRPAATKKAGQAKKKK (SEQ ID NO: 3).

[0060] In other embodiments, the targeting endonuclease may include at least one cell-penetrating domain. In one embodiment, the cell-penetrating domain may be a cell-penetrating peptide sequence derived from the HIV-1 TAT protein. As an example, the TAT cell-penetrating sequence may be GRKKRRQRRRPPQPKKKRKV (SEQ ID NO: 4). In another embodiment, the cell-penetrating domain may be TLM (PLSSIFSRIGDPPKKKRKV; SEQ ID NO: 5), a cell-penetrating peptide sequence derived from human Hepatitis B virus. In yet another embodiment, the cell-penetrating domain may be MPG (GALFLGWLGAAGSTMGAPKKKRKV; SEQ ID NO: 6, or GALFLGFLGAAGSTMGAWSQPKKKRKV; SEQ ID NO: 7). In additional embodiments, the cell-penetrating domain may be Pep-1 (KETWWETWWTEWSQPKKKRKV; SEQ ID NO: 8), VP22, a cell-penetrating peptide derived from herpes simplex virus, or a polyarginine peptide sequence.

[0061] In yet other embodiments, the targeting endonuclease may comprise at least one marker domain. Non-limiting examples of marker domains include fluorescent proteins, purification tags, and epitope tags. In some embodiments, the marker domain may be a fluorescent protein. Non-limiting examples of suitable fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreen1), yellow fluorescent proteins (e.g., YFP, EYFP, Citrine, Venus, YPet, PhiYFP, ZsYellow1), blue fluorescent proteins (e.g., BFP, EBFP, EBFP2, Azurite, mKalama1, GFPuv, Sapphire, T-sapphire), cyan fluorescent proteins (e.g., ECFP, Cerulean, CyPet, AmCyan1, Midoriishi-Cyan), red fluorescent proteins (e.g., mKate, mKate2, mPlum, DsRed), and the like. Monomeric, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRed1, AsRed2, eqFP611, mRasberry, mStrawberry, Jred), and orange fluorescent protein (e.g., mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato) or any other suitable fluorescent protein. In other embodiments, the marker domain can be a purification tag, and / or an epitope tag.Suitable tags include, but are not limited to, glutathione-S-transferase (GST), chitin-binding protein (CBP), maltose-binding protein, thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tags, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, HA, nus, Softag1, Softag3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, 6xHis, biotin carboxyl carrier protein (BCCP), and calmodulin.

[0062] The one or more additional domains can be located at the N-terminus, C-terminus, or internally of the targeting endonuclease. Alternatively, the one or more additional domains can be fused directly to the targeting endonuclease or fused via a linker. Examples of suitable linkers are known in the art, and programs for designing linkers are readily available (Crasto et al., Protein Eng., 2000, 13(5):309-312).

[0063] The above-described targeting endonucleases can be expressed in and purified from eukaryotic or bacterial cells using techniques known in the art.

[0064] (viii) a nucleic acid encoding a targeting endonuclease In some embodiments, the targeting endonuclease is introduced into the cell as a nucleic acid encoding the targeting endonuclease. The nucleic acid encoding the targeting endonuclease can be DNA or RNA, linear or circular, single-stranded or double-stranded. The RNA or DNA can be codon-optimized for efficient translation into protein in the eukaryotic cell of interest. Codon optimization programs are available as freeware or from commercial sources. In some embodiments, the nucleic acid encoding the targeting endonuclease can be mRNA. The mRNA encoding the targeting endonuclease can be transcribed in vitro and purified for introduction into the cell. The mRNA can be 5'-capped and / or 3'-polyadenylated. In other embodiments, the nucleic acid encoding the targeting endonuclease can be DNA. The DNA sequence encoding the targeting endonuclease can be operably linked to at least one promoter regulatory sequence for expression in the cell of interest. In further embodiments, the DNA sequence encoding the targeting endonuclease may also be linked to a polyadenylation signal (e.g., SV40 polyA signal, bovine growth hormone (BGH) polyA signal, etc.) and / or at least one transcription termination sequence.

[0065] In some embodiments, the coding sequence, which is DNA, can be operably linked to a eukaryotic promoter sequence for expression in a eukaryotic cell of interest. The eukaryotic promoter regulatory sequence can be constitutive, regulated, or cell or tissue specific. Suitable eukaryotic constitutive promoter regulatory sequences include, but are not limited to, cytomegalovirus immediate early promoter (CMV), simian virus (SV40) promoter, adenovirus major late promoter, Rous sarcoma virus (RSV) promoter, mouse mammary tumor virus (MMTV) promoter, phosphoglycerate kinase (PGK) promoter, elongation factor (ED1)-alpha promoter, ubiquitin promoter, actin promoter, tubulin promoter, immunoglobulin promoter, fragments thereof, or any combination of the foregoing. Examples of suitable eukaryotic regulated promoter regulatory sequences include, but are not limited to, those regulated by heat shock, metals, steroids, antibiotics, or alcohol. Non-limiting examples of tissue-specific promoters include B29 promoter, CD14 promoter, CD43 promoter, CD45 promoter, CD68 promoter, desmin promoter, elastase-1 promoter, endoglin promoter, fibronectin promoter, Flt-1 promoter, GFAP promoter, GPIIb promoter, ICAM-2 promoter, INF-β promoter, Mb promoter, NphsI promoter, OG-2 promoter, SP-B promoter, SYN1 promoter, and WASP promoter. The promoter sequence may be wild-type or modified for more efficient or effective expression.

[0066] In various embodiments, the DNA encoding the targeting endonuclease may be present in a DNA construct. Suitable constructs include plasmid vectors, phagemids, cosmids, artificial / minichromosomes, transposons, and viral vectors (e.g., lentiviral vectors, adeno-associated viral vectors, etc.). In one embodiment, the DNA encoding the targeting endonuclease is present in a plasmid vector. Non-limiting examples of suitable plasmid vectors include pUC, pBR322, pET, pBluescript, and variants thereof. The vector may include additional expression control sequences (e.g., promoter sequences, enhancer sequences, Kozak sequences, polyadenylation sequences, transcription termination sequences, etc.), selection marker sequences (e.g., antibiotic resistance genes), origins of replication, etc. For additional information, see "Current Protocols in Molecular Biology" Ausubel et al., John Wiley & Sons, New York, 2003, or "Molecular Cloning: A Laboratory Manual" Sambrook & Russell, Cold Spring Harbor Press, Cold Spring Harbor, NY, 3 rd This can be found in the 2001 edition.

[0067] In the embodiment where the targeting endonuclease is a CRISPR / CAS protein or a variant thereof, the expression vector comprising the DNA sequence encoding the CRISPR / CAS protein or a variant thereof may further comprise a DNA sequence encoding one or more guide RNAs. In general, the sequence encoding the guide RNA may be operably linked to at least one transcriptional regulatory sequence for the expression of the guide RNA in the cell of interest. For example, the DNA encoding the guide RNA may be operably linked to a promoter sequence recognized by RNA polymerase III (Pol III). Examples of suitable Pol III promoters include, but are not limited to, mammalian U6, U3, H1, and 7SL RNA promoters.

[0068] Introduction into cells The method includes introducing into a cell (i) a targeting endonuclease or a nucleic acid encoding the targeting endonuclease, and (ii) a donor polynucleotide comprising an exogenous sequence. In an embodiment in which the targeting nuclease is a protein (i.e., ZFN, TALEN, meganuclease), the targeting nuclease can be introduced into the cell as (i) a purified protein, (ii) a coding RNA, or (iii) a coding DNA. In an embodiment in which the targeting endonuclease is a CRISPR / CAS system, the targeting endonuclease can be introduced into the cell as (i) a protein-guide RNA complex, (ii) a protein together with the DNA encoding the guide RNA, (iii) an RNA encoding the CRISPR / CAS nuclease together with the DNA encoding the guide RNA, or (iv) a DNA encoding both the nuclease and the guide RNA.

[0069] Targeting endonuclease molecule and donor polynucleotide can be introduced into cells by various means.Suitable delivery means include microinjection, electroporation, sonoporation, microprojectile gun, calcium phosphate mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary drug enhanced nucleic acid uptake, and delivery via liposome, immunoliposome, virosome, or artificial virion.In certain embodiments, targeting endonuclease molecule and donor polynucleotide are introduced into cells by nucleofection.

[0070] In the embodiment in which one or more targeting endonuclease molecules and one or more donor polynucleotides are introduced into cells, these molecules can be introduced simultaneously or sequentially.For example, the targeting endonuclease molecules specific to each target site and the donor polynucleotide can be introduced simultaneously.Alternatively, each targeting endonuclease molecule and the donor polynucleotide can be introduced sequentially.

[0071] cell culture The method further comprises maintaining the cells under conditions suitable for the exogenous sequence to be integrated into the target site of the genomic sequence. In an embodiment in which the exogenous sequence in the donor polynucleotide is flanked by sequences having substantial sequence identity to sequences flanking the target site in the genomic sequence, the targeting endonuclease introduces a double-stranded break at the target site in the genomic sequence, and the exogenous sequence is integrated into the genomic sequence by a homologous sequence-directed process. In an embodiment in which the exogenous sequence in the donor polynucleotide is flanked by sequences recognized by the targeting endonuclease, the targeting endonuclease introduces a double-stranded break at the target site in the genomic sequence and at the recognition sequences flanking the exogenous sequence in the donor polynucleotide, and the exogenous sequence is integrated into the genomic sequence by a direct ligation process.

[0072] Generally, cells are maintained under suitable conditions for cell growth and / or maintenance. Suitable cell culture conditions are known in the art and described, for example, in Santiago et al. (2008) PNAS 105:5809-5814, Moehle et al. (2007) PNAS 104:3055-3060, Urnov et al. (2005) Nature 435:646-651, and Lombardo et al. (2007) Nat.Biotechnology 25:1298-1306. Those skilled in the art will appreciate that methods for culturing cells are known in the art and may vary depending on the type of cell. In any case, routine optimization may be performed to determine the best technique for a particular cell type.

[0073] Integration of the exogenous sequence may be confirmed by PCR (e.g., junction PCR), DNA sequencing, flow cytometry (e.g., if the exogenous sequence further comprises a sequence encoding a fluorescent protein), selection techniques (e.g., if the exogenous sequence further comprises an antibiotic resistance gene), and other methods known in the art.

[0074] The exogenous sequence is stably integrated into the genome of the cell. In particular, the integrated sequence remains in the genomic locus and is not excised or altered in any way. For example, the integrated sequence and / or adjacent sequences are not subject to gene silencing or position effects. In addition, the integrated exogenous sequence does not affect the function of genes or other chromosomal sequences in the cell, i.e., does not alter global or local gene expression, does not cause cellular abnormalities or defects, does not induce positional mutagenesis or other side effects, etc. The integrated sequence can function predictably and reliably. For example, if the exogenous sequence encodes a protein or an RNA molecule, the expression of the exogenous sequence is stable, efficient, consistent, and predictable. Alternatively, if the exogenous sequence contains one or more recognition sequences for a polynucleotide modifying enzyme, the exogenous sequence can be used as a landing pad for subsequent integration of a sequence of interest.

[0075] (f) Cell type. Suitable cells include mammalian cells or mammalian cell lines. Non-limiting examples of suitable mammalian cells include Chinese hamster ovary (CHO) cells; mouse myeloma NS0 cells; baby hamster kidney (BHK) cells; mouse embryonic fibroblast 3T3 cells (NIH3T3), mouse B lymphoma A20 cells; mouse melanoma B16 cells; mouse myoblast C2C12 cells; mouse myeloma SP2 / 0 cells; mouse embryonic mesenchymal C3H-10T1 / 2 cells; mouse carcinoma CT26 cells, mouse prostate DuCuP cells; mouse breast EMT6 cells; mouse hepatoma Hepa1c1c7 cells; mouse myeloma J5582 cells; mouse epithelial MTD-1A cells; mouse cardiac MyEnd cells; mouse kidney RenCa cells; mouse pancreatic RIN-5F cells; mouse melanoma X64 cells; mouse lin Mammalian cell lines include mammalian cell lines such as human ovarian tumor YAC-1 cells, rat glioblastoma 9L cells, rat B-lymphoma RBL cells, rat neuroblastoma B35 cells, rat hepatoma cells (HTC), buffalo rat liver BRL3A cells, canine kidney cells (MDCK), canine mammary gland (CMT) cells, rat osteosarcoma D17 cells, rat monocyte / macrophage DH82 cells, monkey kidney SV-40 transformed fibroblast (COS7) cells, monkey kidney CVI-76 cells, African green monkey kidney (VERO-76) cells, human embryonic kidney cells (HEK293, HEK293T), human cervical carcinoma cells (HELA), human lung cells (W138), human hepatocytes (HepG2), human U2-OS osteosarcoma cells, human A549 cells, human A-431 cells, or human K562 cells. An extensive list of mammalian cell lines may be found in the American Type Culture Collection Catalog (ATCC, Manassas, VA).

[0076] In various embodiments, the cell line can be deficient in glutamine synthetase (GS), dihydrofolate reductase (DHFR), hypoxanthine-guanine phosphoribosyltransferase (HPRT), or a combination thereof. For example, chromosomal sequences encoding GS, DHFR, and / or HPRT can be inactivated. In certain embodiments, all chromosomal sequences encoding GS in the cell line are inactivated.

[0077] In an exemplary embodiment, the cell is a Chinese Hamster Ovary (CHO) cell. Numerous CHO cell lines are available from the American Type Culture Collection (ATCC). Suitable CHO cell lines include, but are not limited to, CHO-K1 cells and their derivatives. In some embodiments, the CHO cell line can be CHOZN GS- / -, CHO-DXB11, CHO-DG44, CHO-S, or CHO-K1SV.

[0078] definition Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs. The following references provide those skilled in the art with the general definitions of many terms used in the present invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed.1994), The Cambridge Dictionary of Science and Technology (Walker ed.,1988), The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991), and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them unless otherwise specified.

[0079] When introducing elements of the disclosure or preferred embodiments thereof, the articles "a," "an," "the," and "said" are intended to mean that there are one or more elements. The terms "comprising," "including," and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

[0080] As used herein, the term "endogenous sequence" refers to a chromosomal sequence that is native to a cell.

[0081] The term "exogenous sequence" refers to a chromosomal sequence that is not native to the cell or that has been moved to a different chromosomal location.

[0082] A "genetically modified" cell refers to a cell whose genome has been modified, i.e., the cell contains at least one chromosomal sequence that has been engineered to contain at least one nucleotide insertion, at least one nucleotide deletion, and / or at least one nucleotide substitution.

[0083] The terms "genome modification" and "genome editing" refer to a process by which a particular chromosomal sequence is altered such that the chromosomal sequence is modified. The chromosomal sequence may be modified to include an insertion of at least one nucleotide, a deletion of at least one nucleotide, and / or a substitution of at least one nucleotide. The modified chromosomal sequence is inactivated so that no product is produced. Alternatively, the chromosomal sequence may be modified so that an altered product is produced.

[0084] As used herein, "gene" refers to a DNA region (including exons and introns) that encodes a gene product, as well as all DNA regions that regulate the production of the gene product, whether or not such regulatory sequences are adjacent to the coding and / or transcribed sequence. As a result, genes include, but are not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, origins of replication, matrix attachment sites, and locus control regions.

[0085] The term "xenogeneic" refers to something that is not native to the cell or species of interest.

[0086] The terms "nucleic acid" and "polynucleotide" refer to deoxyribonucleotide or ribonucleotide polymers in linear or circular conformation. For the purposes of this disclosure, these terms are not to be construed as limiting with respect to the length of the polymer. The terms can encompass known analogs of natural nucleotides, as well as nucleotides modified at the base, sugar and / or phosphate moieties. In general, an analog of a particular nucleotide has the same base pairing specificity, i.e., an analog of A will base pair with T. The nucleotides of a nucleic acid or polynucleotide may be linked by phosphodiester, phosphothioate, phosphoramidite, or phosphorodiamidite bonds, or combinations thereof.

[0087] The term "nucleotide" refers to deoxyribonucleotides or ribonucleotides. The nucleotides may be standard nucleotides (i.e., adenosine, guanosine, cytidine, thymidine, and uridine) or nucleotide analogs. Nucleotide analogs refer to nucleotides with modified purine or pyrimidine bases or modified ribose moieties. Nucleotide analogs may be naturally occurring nucleotides (e.g., inosine) or non-naturally occurring nucleotides. Non-limiting examples of modifications of the sugar or base moieties of a nucleotide include the addition (or removal) of acetyl, amino, carboxyl, carboxymethyl, hydroxyl, methyl, phosphoryl, and thiol groups, and the replacement of carbon and nitrogen atoms of the base with other atoms (e.g., 7-deazapurines). Nucleotide analogs also include dideoxynucleotides, 2'-O-methyl nucleotides, locked nucleic acids (LNA), peptide nucleic acids (PNA), and morpholinos.

[0088] The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues.

[0089] As used herein, the term "target site" or "target sequence" refers to a nucleic acid sequence that defines a portion of a chromosomal or genomic sequence to be modified or edited, and which a targeting endonuclease has been engineered to recognize, bind to, and cleave, given sufficient conditions for binding and cleavage.

[0090] The terms "upstream" and "downstream" refer to positions within a nucleic acid sequence relative to a fixed position. Upstream refers to the region that is 5' to the position (i.e., closer to the 5' end of the strand) and downstream refers to the region that is 3' to the position (i.e., closer to the 3' end of the strand).

[0091] Techniques for determining the identity of nucleic acid and amino acid sequences are known in the art. Typically, such techniques involve determining the nucleotide sequence of the mRNA for a gene and / or determining the amino acid sequence encoded thereby, and comparing these sequences to a second nucleotide or amino acid sequence. Genomic sequences can also be determined and compared in this manner. In general, identity refers to the exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotide or polypeptide sequences, respectively. Two or more sequences (polynucleotide or amino acid) can be compared by determining their percent identity. The percent identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between the two aligned sequences divided by the length of the shorter sequence, multiplied by 100. Approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be applied to amino acid sequences using a scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, MO Dayhoff ed., 5 suppl. 3: 353-358, National Biomedical Research Foundation, Washington, DC, USA, and normalized by Gribskov, Nucl. Acids Res. 14(6): 6745-6763 (1986). An exemplary implementation of this algorithm for determining percent identity of sequences is provided in the "Best Fit" utility application by the Genetics Computer Group (Madison, Wis.). Other suitable programs for calculating percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters.For example, BLASTN and BLASTP can be used with the following default parameters: genetic code=normal, filter=none, strand=both, cutoff=60; expectation=10, matrix=BLOSUM62, description=50 sequences, sort=high score, database=no redundancy, GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+Swiss protein+Spupdate+PIR. Details of these programs can be found on the GenBank website. For the sequences described herein, the desired degree of sequence identity ranges from about 80% to 100%, and any integer value therebetween. Typically, the percent identity between sequences is at least 70 to 75%, preferably 80 to 82%, more preferably 85 to 90%, even more preferably 92%, even more preferably 95%, and most preferably 98% sequence identity.

[0092] Since various modifications can be made to the above cells and methods without departing from the scope of the present invention, all matter contained in the above description and the examples set forth below is intended to be interpreted as illustrative and not in a limiting sense. EXAMPLES

[0093] Working Example The following examples illustrate certain aspects of the invention.

[0094] Example 1: Identification of the genomic locus of randomly integrated transgenes in CHO cell lines Approach 1. Random integration of plasmid CLE385 (see Figure 1A), which contains a GFP expression cassette landing pad flanked by Lox sites Lox71 and Lox2272. Single copy clones with high GFP expression were identified and evaluated. Genomic sequences flanking the integration event were then blasted against available CHO databases to determine the contig accession numbers and positions within the contigs of the randomly integrated landing pad.

[0095] Approach 2. Random integration of plasmid CLE399, which contains a monoclonal antibody expression cassette landing pad flanked by Lox sites, LoxP and LoxN at 5', and Lox2272 at 3' (see Figure 1B). mAb high-expressing single copy clones were identified and evaluated. Recombinase-mediated cassette exchange (RMCE) was then used to exchange the GFP expression cassette CLE416, and GFP high-expressing clones were identified and evaluated (see Figure 1B). Genomic sequences flanking the integration event were blasted against available CHO databases to determine the contig accession numbers and positions within the contigs of the randomly integrated landing pad.

[0096] The results are shown in Table 1. [Table 1]

[0097] Example 2 Evaluation of genomic locus D145 A clone with the landing pad CLE385 (clone D145) was isolated. Recombinase-mediated cassette exchange (RMCE) was performed in this clone. Briefly, a plasmid donor (CLE389, Figure 1A) containing a mAb cassette flanked by Lox sites compatible with the landing pad CLE385 was electroporated into this clone together with Cre mRNA. After successful RMCE, the CLE385 landing pad would have been exchanged with the CLE389 donor cassette. After glutamine selection, the resulting pool was analyzed by flow cytometry (Figure 2) and compared with the D145 parent clone and with a pool generated using only the donor without Cre mRNA addition. Compared to the donor-only pool, the majority of cells in the RMCE pool had shifted from GFP expression to mAb expression. PCR primers were designed such that the amplification event would occur only if the mAb expression cassette was specifically and correctly inserted into the D145 locus. Amplification was successful at both 5-prime and 3-prime junctions (Fig. 3 ).

[0098] Example 3 Evaluation of the MP7 genomic locus The MP7 site was identified in approach 2 and retargeted with CLE416 to generate a pool containing cells with a GFP landing pad. This pool was then targeted with a mAb expression plasmid containing the corresponding Lox site and tested for antibody secretion. Efforts to retarget MP7 with ZFNs and novel landing pads are ongoing (Figure 4).

[0099] Example 4 Evaluation of genomic locus MP58 The MP58 site was identified in approach 2 and retargeted with CLE416 to generate a pool containing cells bearing a GFP landing pad, and a ZNF was designed to place a novel landing pad at this site (Figure 5).

[0100] Production of monoclonal antibodies originating from the MP58 site in early and late cultures was measured by standard growth and productivity assays. Briefly, 3x10 5 Cell cultures of 30 ml were initiated at an initial seeding density of 100 cells / ml and grown under standard feeding conditions with periodic supplementation. Cell cultures were harvested and analyzed for the concentration of secreted monoclonal antibodies while monitoring growth and viability (ForteBio Octet, Figure 6).

Claims

1. A method for stably integrating at least one exogenous sequence into genomic DNA of a Chinese hamster ovary (CHO) cell, the method comprising integrating the at least one exogenous sequence into a site within the genomic sequence of NCBI reference sequence, NW_003613732.1, scaffold 1721: bp 1,935,000 to bp 1,985,000.

2. The method of claim 1, wherein at least one exogenous sequence encodes a protein or an RNA molecule.

3. The method of claim 2, wherein the protein is a therapeutic protein, a recombinant protein, or an industrial protein.

4. The method described in claim 2, wherein the RNA molecule is a small interfering RNA (siRNA), microRNA (miRNA), guide RNA (gRNA), or a precursor thereof.

5. A method according to any one of claims 2-4, wherein the at least one exogenous sequence is operably linked to a promoter regulatory sequence.

6. The method of claim 1, wherein the at least one exogenous sequence comprises at least one recognition sequence for a polynucleotide modifying enzyme.

7. The method of claim 6, wherein at least one recognition sequence comprises a nucleic acid sequence that is not endogenously present in the genome of a mammalian cell.

8. The method of claim 6, wherein the polynucleotide modifying enzyme is a site-specific recombinase or a targeting endonuclease.

9. The method of claim 8, wherein the site-specific recombinase is Bxb1 integrase, Cre recombinase, FLP recombinase, gamma delta resolvase, lambda integrase, phi C31 integrase, R4 integrase, Tn3 resolvase, or TP901-1 recombinase.

10. The method of claim 8, wherein the targeting endonuclease is a zinc finger nuclease (ZFN), a clustered regularly interspersed short palindromic repeats (CRISPR) / CRISPR-associated (Cas) (CRISPR / Cas) nuclease system, a CRISPR / Cas dual nickase system, a transcription activator-like effector nuclease (TALEN), a meganuclease, or a fusion protein comprising a programmable DNA-binding domain and a nuclease domain.

11. A method for preparing a Chinese hamster ovary (CHO) cell comprising an exogenous sequence integrated into its genomic DNA, comprising: a) introducing into a cell (i) a targeting endonuclease or a nucleic acid encoding a targeting endonuclease that targets a target site within the genomic sequence of NCBI Reference Sequence, NW_003613732.1, Scaffold 1721: bp 1,935,000 to bp 1,985,000, and (ii) a donor polynucleotide comprising the exogenous sequence; and b) maintaining the cells under conditions such that the exogenous sequence is integrated into the target site of the genomic sequence; A method comprising:

12. The method described in claim 11, wherein the exogenous sequence in the donor polynucleotide is flanked by sequences having at least 95% sequence identity to sequences flanking the target site in the genomic sequence.

13. The method of claim 12, wherein the exogenous sequence is integrated into the genome by a homologous sequence directed process.

14. The method described in claim 12 or 13, wherein the exogenous sequence in the donor polynucleotide is flanked by sequences recognized by at least one of the targeting endonucleases.

15. The method of claim 14, wherein the exogenous sequence is integrated into the genome by a direct ligation process.

16. The method of any one of claims 11-15, wherein the targeting endonuclease is a zinc finger nuclease (ZFN), a clustered regularly interspersed short palindromic repeats (CRISPR) / CRISPR-associated (Cas) (CRISPR / Cas) nuclease system, a CRISPR / Cas dual nickase system, a transcription activator-like effector nuclease (TALEN), a meganuclease, or a fusion protein comprising a programmable DNA-binding domain and a nuclease domain.

17. The method of any one of claims 11-16, wherein the exogenous sequence encodes a protein or an RNA molecule.

18. The method of claim 17, wherein the protein is a therapeutic protein, a recombinant protein, or an industrial protein.

19. The method described in claim 17, wherein the RNA molecule is a small interfering RNA (siRNA), microRNA (miRNA), guide RNA (gRNA), or a precursor thereof.

20. The method of any one of claims 17-19, wherein the exogenous sequence is operably linked to a promoter regulatory sequence.